Catch the latest from #OncologyUnscripted! John Marshall breaks down the biggest practice-changing updates you need to know. New standards are here: IO + chemo is now the move for MSI-high colon cancer, IO’s making waves in gastric and head & neck, and ctDNA is helping us stay

🎙️ Catching up on the latest in oncology? #OncologyUnscripted with John Marshall delivers a fresh take on what’s happening in the world of cancer care, from cutting-edge science and business updates to clinical insights and a bit of behind-the-scenes buzz. 🧠 Don’t miss the mix

Join us to review research from the #ASCO25 Annual Meeting. John Marshall, Benjamin Weinberg, MD, FACP, Marcus S. Noel, and Reetu Mukherji, MD will highlight the most compelling abstracts in Colorectal, Pancreatic, Liver, and Upper GI cancers via Zoom this Friday, June 27th. Register today:

Panelists John Marshall, Dr. Marwan G. Fakih, Arvind Dasari, MD, MS, and Katrina Pedersen, MD, MS discuss how the BREAKWATER trial demonstrates that upfront treatment with encorafenib plus cetuximab significantly improves outcomes in BRAF V600E-mutated CRC. onclive.com/view/expert-in… via @onclive

“Colorectal cancer is the second leading cause of cancer-related deaths, and incidence is rising in young adults,” said John Marshall. "Research is critical to better understanding the rise in CRC cases, discovering advancements in care, and overcoming this disease.” Colorectal Cancer Alliance

Panelists John Marshall, Dr. Marwan G. Fakih, Arvind Dasari, MD, MS, and Katrina Pedersen, MD, MS discuss how doublet immunotherapy with ipilimumab and nivolumab provides superior outcomes compared to single-agent PD-1 therapy or chemotherapy in microsatellite instability-high colorectal cancer, supporting the

Join us tomorrow morning to review research from the #ASCO25 Annual Meeting. John Marshall, Benjamin Weinberg, MD, FACP, Marcus S. Noel, and Reetu Mukherji, MD will highlight the most compelling abstracts in Colorectal, Pancreatic, Liver, and Upper GI cancers via Zoom on Friday, June 27th. Register

Panelists John Marshall, Dr. Marwan G. Fakih, Arvind Dasari, MD, MS, and Katrina Pedersen, MD, MS discuss the role of ctDNA in the Management of mCRC. onclive.com/view/the-role-… via @onclive

Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors (TKI) with John Marshall and AnswersinCME. Learn more today: answersincme.com/KTK. #GetYourAnswersInCME #AiCME

It was lovely speaking to Benjamin Weinberg, MD, FACP (Georgetown University) who shared findings on BXCL701 plus pembrolizumab efficacy and safety in 2L advanced #PDAC, plus insights on current second-line treatment decision-making and therapeutic selection factors Watch at VJOncology.com 👀

"After 20 years of leadership, John Marshall, will be stepping down as the division chief of Medical Oncology at MedStar Georgetown University Hospital. Dr. Marshall will remain in practice with our GI oncology disease group and will continue to serve as the chief medical officer

📍#ASCO25 marks a turning point in metastatic CRC care. BREAKWATER shows BRAF is no longer just bad news but an effective therapeutic target. First-line molecular profiling for MSI, RAS, BRAF, and HER2 is now the standard. 🔗 Read more from John Marshall: mashupmd.com/expert-collect…

✨ 100% benefit rate, but who actually gets access? In the latest episode of #OncologyUnscripted, Dr. John Marshall dives into why smarter cancer care isn’t just about innovation, it’s about access, equity, and value. From IO therapy for MSI+ rectal cancer to inexpensive

Gastrointestinal cancers have become the fastest-growing type of cancer diagnosed in adults under the age of 50 in the US. Kimmie Ng, MD, MPH, John Marshall, Scott Kopetz, and Howard S Hochster MD discuss this trend and why research is critical to uncovering the possible causes. nbcnews.com/health/health-…

In the latest episode of #OncologyUnscripted, Dr. John Marshall dives into why smarter cancer care isn’t just about innovation; it’s about access, equity, and value. He explores how we can deliver better, more efficient care worldwide, from IO therapy for MSI+ rectal cancer to

Panelists John Marshall, Dr. Marwan G. Fakih, Arvind Dasari, MD, MS, and Katrina Pedersen, MD, MS review treatment options in third-line mCRC and therapy sequencing strategies. onclive.com/view/a-review-… via @onclive

Remembering Dr. John S. Macdonald, 2018 Cure GI Cancers Luminary Award recipient and former Georgetown Lombardi faculty, in recognition of his contributions to the care of patients with gastrointestinal cancer. The Macdonald regimen was considered standard of care for the adjuvant

🧬Precision medicine is changing CRC care fast. @Marshalj23 highlights why frontline testing for RAS, BRAF, HER2, and MSI is now essential. BREAKWATER shows BRAF can guide treatment, not just predict poor outcomes. ➡️mashupmd.com/expert-collect…

Dr John Marshall sits down with an international leader in oncology—Dr David Kerr to explore how cost, policy, and infrastructure shape access to cutting-edge cancer care worldwide. Watch the full interview here: bit.ly/4m8CwpI #OncologyInsights #CancerCare

The challenge isn’t discovering innovation...it’s delivering it. As Dr. John Marshall asks: How do we take breakthrough data, whether FDA-approved, added to NCCN, or not yet covered by insurance, and actually apply it to patient care? In many cases, these novel tests and